Tender detail
Conclusion of a Non-Exclusive Discount Agreement for Medicinal Products Containing Dapagliflozin
Summary
The tender concerns the conclusion of non-exclusive pharmaceutical discount agreements for medicinal products containing the active substance dapagliflozin (ATC A10BK01). The agreements are intended to run from 1 October 2026 to 30 September 2028, but will end automatically if an exclusive agreement for the substance enters into force. Interested pharmaceutical companies may participate, and the bidder must identify the relevant medicinal products in the contract annex. Precise exclusion, qualification and compliance requirements must be checked in the official tender documents.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.